
Daraxonrasib Pancreatic Cancer Trial: Tumours Shrank in 60.7% of Patients
A daraxonrasib pancreatic cancer combination shrank tumours in 60.7% of previously untreated patients whose disease had spread, according to updated trial results presented on Friday 20 November 2026 in Barcelona, Spain. Revolution Medicines announced the Phase 1/2 RMC-GI-102 findings on Thursday 19 November 2026, ahead of a late-breaking oral session at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Dr Wungki Park of Memorial Sloan Kettering Cancer Center in New York presented the data for patients receiving daraxonrasib, sold as Rasonque, together with standard chemotherapy. The results matter because metastatic pancreatic cancer has resisted new treatments for decades, and doctors at the meeting described the depth and length of disease control as unusual for this setting.
Daraxonrasib Pancreatic Cancer Trial — Quick Reference Summary
| Detail | What is known |
|---|---|
| Drug combination | Daraxonrasib (Rasonque) 200 mg by mouth once daily plus gemcitabine and nab-paclitaxel |
| Trial | RMC-GI-102 Phase 1/2, first-line metastatic pancreatic adenocarcinoma cohort |
| Patients treated | 61 people who had not received prior treatment for metastatic disease |
| Data cutoff | Monday 28 September 2026, median follow-up 18.3 months |
| Tumours shrank or disappeared | 60.7% of patients, including complete responses in 8.2% |
| Disease controlled | 90.2% of patients |
| Median time before growth resumed | 12.8 months |
| Alive at 12 months | Estimated 76.6% |
| Next test | Phase 3 RASolute 303 trial against chemotherapy alone |
| UK first-line availability | Not publicly verified |
What the Barcelona Numbers Actually Show
The updated analysis covers 61 patients treated with daraxonrasib plus gemcitabine and nab-paclitaxel, known together as GnP. Tumours shrank or disappeared in 60.7% of patients, and in 8.2% the tumours were no longer detectable on scans.
Disease stopped growing in 90.2% of patients overall. The median time before tumours returned or started growing again reached 12.8 months, and the estimated share of patients alive at one year was 76.6%.
| Measure | RMC-GI-102 updated result |
|---|---|
| Objective response rate | 60.7% (95% CI 47.3–72.9) |
| Complete responses | 8.2% |
| Disease control rate | 90.2% (95% CI 79.8–96.3) |
| Median duration of response | 11.1 months |
| Median progression-free survival | 12.8 months |
| Estimated 12-month overall survival | 76.6% |
For context, standard chemotherapy alone shrinks tumours in roughly 23% to 42% of patients with metastatic pancreatic cancer, with growth often resuming after five to six months. Historical overall survival with conventional chemotherapy sits around 8.5 to 11.1 months, which is why a median beyond one year drew attention in Barcelona.
How Daraxonrasib Targets the RAS Switch
More than 90% of pancreatic cancers carry a mutation in the RAS gene, which acts like a growth switch inside cells. In pancreatic cancer that switch stays stuck on, sending constant signals for cancer cells to divide and grow.
Daraxonrasib is an oral medicine designed to block the active RAS(ON) protein and cut off those survival signals. In the trial, patients took 200 mg once a day, with gemcitabine and nab-paclitaxel given by intravenous injection on days 1 and 15 of each treatment cycle.
Revolution Medicines’ announcement describes daraxonrasib as a RAS(ON) multi-selective inhibitor now being tested in a global Phase 3 programme. The company, listed on Nasdaq as RVMD, says the updated findings support testing the combination as a possible first-line option rather than only after earlier therapy fails.
Side Effects Reported With the Combination
The safety profile matched what doctors already knew about daraxonrasib and GnP separately, with no new safety signal flagged in the update. The most common side effects included rash, diarrhoea and fatigue, alongside chemotherapy effects such as cytopenia, a reduction in some blood cells.
Stopping treatment because of daraxonrasib-related side effects was uncommon, occurring in 5% of patients. A full breakdown of severe Grade 3 or higher side effects for this exact cohort was not included in the November announcement, so that detail remains not publicly verified.
Readers following other safety stories this week will recognise the pattern of regulators and researchers acting on early warning data, from the UK supermarket fridge operation to the Toyota airbag recall. With medicines, the equivalent safeguard is a randomised trial, because early response rates alone cannot prove that patients live longer.
Why Pancreatic Cancer Has Been So Hard to Treat
Pancreatic adenocarcinoma is the most common form of pancreatic cancer and one of the hardest cancers to treat successfully. Around 500,000 people are diagnosed worldwide each year, and it ranks as the seventh leading cause of cancer-related deaths globally.
Early pancreatic cancer often causes few or no symptoms, so roughly 80% of patients learn they have it only after it has spread. For metastatic disease, only about 3% of patients are alive five years after diagnosis, a figure that explains the urgency behind RAS-targeted research.
Dr Park told the symposium that pancreatic cancer remains one of the most challenging cancers to treat, particularly because more than half of patients first present with disease that has already spread. The ecancer report from the symposium records his view that deeper responses and near-doubling of disease control could eventually translate into longer survival, while stressing that proof needs a larger trial.
What Happens Next for Patients and the Drug Maker
The decisive test is already running. The global Phase 3 RASolute 303 trial is comparing daraxonrasib alone and daraxonrasib plus GnP against GnP alone in treatment-naïve metastatic pancreatic cancer, which will show whether adding the drug improves outcomes beyond chemotherapy.
Regulators have already moved on parts of the programme. Daraxonrasib as a single medicine is approved in the United States for adults whose metastatic pancreatic cancer has already received at least one prior therapy, and the combination holds FDA Breakthrough Therapy Designation for the first-line setting.
Whether the first-line combination will be approved or funded for routine use in the United Kingdom is not publicly verified. No price for first-line use has been published in the November announcements, and patients should discuss trial eligibility and approved options with their own oncology team rather than acting on conference results alone.
Professor Elena Garralda, chair of the symposium and not involved in the study, called the results exciting because combined treatment could potentially improve both survival and time before tumours grow again. She also noted that RAS mutations drive certain lung, bowel and other cancers, though each disease would need its own trial before any wider use could be considered.
Questions Readers Are Asking About Daraxonrasib
What is daraxonrasib?
Daraxonrasib, sold as Rasonque, is a once-daily oral medicine from Revolution Medicines that blocks the active RAS(ON) protein driving many pancreatic cancers. In RMC-GI-102 it was combined with gemcitabine and nab-paclitaxel chemotherapy for people receiving their first treatment for metastatic disease.
How well did the combination work in the trial?
Tumours shrank or disappeared in 60.7% of the 61 patients, with complete responses in 8.2% and disease control in 90.2%. The median time before tumours grew again was 12.8 months, and an estimated 76.6% of patients were alive at 12 months.
Is daraxonrasib a cure for pancreatic cancer?
No. Complete responses in a small early-phase trial mean tumours were no longer detectable at that point, not that cancer was cured. The study had no comparison group receiving chemotherapy alone, so survival benefit remains unproven until Phase 3 results arrive.
Can patients in the UK get daraxonrasib now?
First-line combination availability in the United Kingdom is not publicly verified. Single-medicine approvals cover patients who have already received prior therapy in the United States and European Union, and access routes differ by country and health system.
What side effects were most common?
Rash, diarrhoea, fatigue and chemotherapy-related blood-cell reductions were the most common effects reported. About 5% of patients stopped treatment because of daraxonrasib-related side effects, and doctors managed most effects with standard supportive care.
Claims Worth Checking Before Sharing
Claim: “A new drug cures pancreatic cancer.” The trial showed tumour shrinkage, including complete responses in 8.2% of patients, in an early-phase study without a control group. That is promising evidence for further testing, not proof of a cure.
Claim: “Daraxonrasib doubles survival.” Median progression-free survival of 12.8 months exceeds historical chemotherapy figures of five to six months for disease control, but overall survival benefit versus chemotherapy alone has not yet been shown. The Phase 3 RASolute 303 trial is designed to answer that question.
Claim: “The drug is already available everywhere.” Approvals so far cover single-medicine use after prior therapy in the United States and European Union. First-line combination approval, UK availability and pricing remain not publicly verified.



